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Abstract
Somatic mutations in the nuclear genome are required for tumor formation, but the func-
tional consequences of somatic mitochondrial DNA (mtDNA) mutations are less under-
stood. Here we identify somatic mtDNA mutations across 527 tumors and 14 cancer types,
using an approach that takes advantage of evidence from both genomic and transcriptomic
sequencing. We find that there is selective pressure against deleterious coding mutations,
supporting that functional mitochondria are required in tumor cells, and also observe a
strong mutational strand bias, compatible with endogenous replication-coupled errors as
the major source of mutations. Interestingly, while allelic ratios in general were consistent in
RNA compared to DNA, some mutations in tRNAs displayed strong allelic imbalances
caused by accumulation of unprocessed tRNA precursors. The effect was explained by
altered secondary structure, demonstrating that correct tRNA folding is a major determinant
for processing of polycistronic mitochondrial transcripts. Additionally, the data suggest that
tRNA clusters are preferably processed in the 30 to 50 direction. Our study gives insights into
mtDNA function in cancer and answers questions regarding mitochondrial tRNA biogenesis
that are difficult to address in controlled experimental systems.
Author Summary
According to the so-called “tRNA punctuation model”, tRNA processing is key to generat-
ing all mature mitochondrial mRNAs. However, the process is difficult to study in vivo,
since standard tools for genetic manipulation are not applicable to mitochondria. Here, we
circumvent this problem by using a large compendium of naturally occurring genetic per-
turbations, derived from human tumor sequencing data. We identify somatic mitochon-
drial mutations across hundreds of human tumors using an approach that simultaneously
takes advantage of both genomic and transcriptomic sequencing. This enables us to com-
pare the allele frequency in DNA and RNA for each mutation. Our data reveals that some
mutations in mitochondrial tRNAs are associated with strong accumulation of immature
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tRNA precursors, indicative of impaired tRNA mutaration. We find that intact tRNA sec-
ondary structure is a major requirement for correct maturation, and that mutations affect-
ing tRNA folding can impair maturation of not only the affected tRNA, but also
neighboring gene transcripts. Mutations in mitochondrial tRNAs underlie a range of dis-
ease conditions, and our findings may help to explain why mutations in the same tRNA
can present different phenotypes. Our results additionally support that there is selective
pressure against mutations affecting oxidative phosphorylation, showing that functional
mitochondria are required in many tumor cells.
Introduction
Under normal conditions, mammalian cells rely on oxidative phosphorylation in mitochondria
to generate most of their supply of adenosine triphosphate (ATP). Cancer cells, in contrast,
typically show increased production of ATP through non-oxidative breakdown of glucose in
the cytoplasm (the Warburg effect) [1], and reprogramming of energy metabolism is now con-
sidered a hallmark of cancer [2]. However, in spite of the Warburg effect, the majority of ATP
is in many tumors still produced via the respiratory chain, and there are also examples of can-
cer cells with increased dependence on oxidative phosphorylation [3].
All tumors arise as a consequence of acquired somatic genetic alterations followed by micro-
evolutionary selection [4]. The study of mutations in tumors has in recent years been greatly
facilitated by massively parallel sequencing, which has provided numerous insights into the
changes in the nuclear genome that underlie cancer [5,6]. However, despite the fact that altered
mitochondrial function is a characteristic property of tumor cells, only a few studies have char-
acterized somatic mutations in the mitochondrial genome in cancer using high-throughput
methodologies [7,8]. These studies have demonstrated that somatic mtDNA mutations are
common in tumor cells [7,8], and that there is a negative selection against mutations that
results in protein truncation, i.e. impair proper oxidative phosphorylation [8].
The 16.6 kb circular human mitochondrial genome harbors 37 genes, of which 13 are pro-
tein-coding, two codes for rRNA, whereas the rest codes for mitochondrial tRNAs (mt-
tRNAs). Transcription is initiated from two major promoter regions, one for the “light” and
one for the “heavy” strand of the DNA molecule (L and H, respectively), generating long poly-
cistronic transcripts that contain the genetic information of the respective strand. The curious
interspacing of the tRNA genes between the mRNAs and rRNAs lead to the hypothesized
“tRNA punctuation model”, whereby the tRNAs are specifically recognized and cleaved out of
these polycistronic transcripts, with the remaining RNAs being matured to the mRNAs or
rRNAs [9,10]. Since then, a more complete understanding of the mRNAmaturation processing
processes and its complexities in mammalian mitochondria has developed [11,12].
In the polycistronic transcripts, the mt-tRNAs encoding regions are identified and pro-
cessed by a 5´ acting mitochondrial RNaseP, a heteromer of theMRPP1- 3, HSD10 gene prod-
ucts [13–15], which is followed by a 3´ processing event carried out by the mitochondrial
RNaseZ (ELAC2) [16,17] and, possibly, PTCD1 [18]. It was hypothesized early on that the
structure and not the sequence of the tRNA may represent the main signal for recognition by
the processing enzymes [9], a notion supported by the fact that the same RNase P appears to
cleave all mt-tRNA precursors [13]. Interestingly, pathogenic mt-tRNA variants appear to
often be located in tRNA stem regions, suggestive of an impact on secondary structure [19],
and there are some examples in the literature of mutations that impair processing while at the
same time affecting mt-tRNA structure [20,21]. Unfortunately, it is has been difficult to study
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this phenomenon in a more systematic way due to difficulty of performing reverse genetics in
mitochondria, and the relationship between pre-tRNA structure and processing in vivo there-
fore remains incompletely understood [22].
Here we make use of whole-genome sequencing (WGS) data from The Cancer Genome
Atlas (TCGA) consortium to map somatic mitochondrial mutations in 527 tumors from 14
types of human cancer. Since most of the mitochondrial genome is transcribed and polyadeny-
lated, we could further refine our mutational map by requiring mutations to be detectable also
in matched transcriptome sequencing (RNA-seq) data from the same tumors. This approach
enabled a comparison of the allelic ratios in DNA to RNA for all mutations, allowing detection
of allelic imbalances that arise when genetic alleles are processed at different rates at the level of
RNA. We found that this was an effective way of pinpointing mutations that lead to tRNAmat-
uration defects, making it possible to use our compendium of somatic mitochondrial DNA
(mtDNA) mutations to gain insight into mt-tRNA processing.
Results
DNA/RNAmapping somatic mitochondrial mutations in 527 tumors
We screened 527 tumors, spanning 14 types of human cancer, for somatic mtDNA mutations
using high-coverage WGS data from TCGA (Table 1; included samples/libraries are listed in
S1 Dataset). Mutations were called by comparing tumors to non-tumor samples from the
same individuals. Due to the multi-copy nature of mtDNA, most mutations showed very high
sequencing coverage (on average>5000 reads), effectively minimizing the risk of contamina-
tion from nuclear DNA pseudogenes of mitochondrial origin (S1 Fig). In addition, mutations
were mapped in polyA+ RNA-seq from the same tumors, confirming 96% of the WGS-based
mutations and resulting in a final set of 616 high-confidence mutations (564 single-nucleotide
variants and 52 small indels) supported by both data types (detailed in S2 Dataset). Of the ana-
lyzed tumors, 335 (64%) had at least one mutation, and the average number of mutations per
Table 1. Overview of included tumors and detected somatic mtDNAmutations.
Code Cancer type Tumors analyzed Total mutations Mutations/tumor Fraction indels
BLCA Bladder 23 43 1.87 7.0%
BRCA Breast 100 123 1.23 7.3%
CRC Colorectal 42 52 1.24 7.7%
GBM Glioblastoma 37 8 0.22 0.0%
HNSC Head & neck 29 29 1.00 13.8%
KICH Kidney (chrom.) 15 17 1.13 17.6%
KIRC Kidney (clear) 29 29 1.00 20.7%
LGG Low-grade glioma 18 8 0.44 12.5%
LUAD Lung (adeno) 46 65 1.41 3.1%
LUSC Lung (squamus) 45 54 1.20 5.6%
PRAD Prostate 19 6 0.32 16.7%
SKCM Melanoma 42 62 1.48 8.1%
THCA Thyroid 35 36 1.03 11.1%
UCEC Uterus 47 84 1.79 8.3%
527 616 1.17 8.4%
527 tumor/normal pairs from 14 cancer types were analyzed for somatic mutations (substitutions and small indels) in mtDNA based on high-coverage
genomic sequencing data, considering mutations with allele frequency >15% in the tumor and <0.5% in the normal that additionally were conﬁrmed in
matched RNA-seq data from the same tumors.
doi:10.1371/journal.pgen.1005333.t001
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tumor (1.17) varied between 0.32 and 1.87 in the individual cancers (Table 1). 363 (59%) of
mutations were in coding regions (69% missense, 19% synonymous, 7% frameshift, and 4%
nonsense).
Earlier high-throughput screens of somatic mitochondrial mutations have presented con-
flicting results regarding positive selection in protein-coding genes [7,8]. We found that the fre-
quency of nonsynonymous mutations did not deviate significantly from the expectation
(P = 0.084, χ2 test with Yates correction), thus providing no clear evidence of positive selection
(S1 Appendix). While several coding positions were recurrently mutated (Fig 1, outward-fac-
ing bars), these were preferably frameshift-causing expansions of mononucleotide repeats,
including insertions at polyC stretches at 10,947–52 and 11,867–72 in the ND4 gene (occurring
in 5 tumors), and indels in a polyA stretch at position 12418–25 in the ND5 gene (in 4 tumors).
These hotspots are likely due to a high susceptibility to polymerase slippage errors rather than
positive selection [23], although some of them have been described and attributed possible
tumorigenic effects [24–26].
Purifying selection acting on mtDNA in tumors
Deleterious coding mitochondrial variants are uncommon in normal tissues [27], confirmed
by analysis of the normal samples included in this study (no nonsense and only a single frame-
shift mutation was detected). The frequencies of damaging somatic mutations reported above
(7% frameshift and 4% nonsense) are thus suggestive of relaxed functional constraints in
tumor tissues. A large meta-analysis of somatic mtDNA mutations in oncocytic tumors indeed
found that the overall pattern of amino acid changes was compatible with a lack of purifying
selection [28]. However, a recent study that took variant allele frequencies into account
reported that deleterious somatic variants were suppressed in human cancers, suggestive of
purifying selection against these reaching high levels of heteroplasmy [8].
Fig 1. Mutational density across the mitochondrial genome. Inward-facing thick bars indicate the number
of mutations per 331 nt segment (50 segments), with substitutions and indels shown in gray and orange,
respectively. 616 somatic mutations, identified across 527 tumors, are shown. Outward-facing bars thin bars
indicate individual recurrently mutated positions (> = 2 tumors).
doi:10.1371/journal.pgen.1005333.g001
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In our DNA/RNA-based compendium of somatic mitochondrial mutations, we found that
heteroplasmy levels varied greatly, at an average of 58.1% and with 8.0% of the 616 mutations
reaching near-homoplasmy (mutant allele frequency>95%; Fig 2). However, frameshifting
indels in coding regions, likely to have a strong negative functional impact, showed clearly
reduced heteroplasmy levels (39.6%; P = 0.0038, two-sample Kolgomorov-Smirnov test), nota-
bly without ever reaching above 85%. A similar trend was seen for nonsense (premature stop)
mutations (48.8%, P = 0.13), while synonymous and missense mutations were comparable to
the full set, also when considering a subset with predicted likely functional impact as defined
using the PolyPhen-2 method [29]. Somatic mutations were detected throughout the mito-
chondrial genome, but the density was clearly higher in the “hypervariable” D-loop region,
where mutations are better tolerated [30] (Fig 1). The nucleotide composition in this region
does not deviate considerably from other parts of the mitochondrial genome [30], and the
result can thus be interpreted as if negative selection is less pronounced in the non-coding D-
loop. In support of this, we found that D-loop mutations showed elevated heteroplasmy levels
(average 65.8%) compared to non-D-loop mutations (P = 0.0083; Fig 2).
Taken together, our data confirms and extends recent results [8], supporting that purifying
selection is at play in coding regions to maintain mitochondrial function in tumors, although
to a lesser extent than in normal tissues. Importantly, while both studies make use of TCGA
data, the sample overlap is small (30/527 tumors; 5.7%) and the results thus largely
independent.
Mutational signatures and replicative strand bias
Insights into the mutational processes that underlie somatic mutations can be gained by ana-
lyzing the sequence properties of the resulting substitutions [31]. We found that mutations
Fig 2. Frameshift indels show reduced heteroplasmy levels indicative of negative selection.
Cumulative distributions of mutant allele frequencies (heteroplasmy levels) for different mutational
categories. Frameshift indels showed significantly reduced levels of heteroplasmy, and never reach above
85%. A similar trend, although non-significant, was seen for missense (stop-inducing) mutations. In contrast,
D-loop mutations, which in general should be more tolerable, showed significantly elevated levels. P-values
were calculated using the two-sample Kolmogorov-Smirnov test, comparing the tumor set of interest to
remaining samples. Missense PP2 refers to a subset of missense mutations predicted to be “probably
damaging” by PolyPhen-2 [29].
doi:10.1371/journal.pgen.1005333.g002
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preferably occurred at CG base pairs (65%; 1.5 expected frequency) in the form of C>T (or
G>A) transitions (S1 Dataset), similar to the typical nuclear mutational profile in tumors [31].
A more detailed analysis revealed a strong strand bias, with C>T transitions on the H-strand
occurring at 10.6 times the expected frequency (Fig 3). This confirms and closely matches the
results of a recent analysis [8]. Strand bias was observed throughout the genome, except in the
D-loop region, where C>T transitions were still overrepresented but not in a strand specific
manner (S2 Fig). The observed strand bias is likely related to differences in the mode of repli-
cation of the two strands [32].
The mutational profile was highly consistent across all 14 cancers, although strand biases
were reduced in melanoma (Fig 3). This could suggest a contribution from an exogenous
mutagenic processes in this cancer; however, arguing against this interpretation, we failed to
observe an elevation in the dipyrimidine signature typical of UV exposure [33] in the flanking
bases. We conclude that endogenous replication errors or other replication-coupled effects are
the dominant source of somatic mutations in tumor mtDNA.
Insights into mt-tRNA processing from DNA/RNA allelic imbalances
The dual genomic/transcriptomic design of our study enabled us to compare allelic ratios (het-
eroplasmy levels) in DNA and RNA, to reveal imbalances that arise when genetic alleles are
Fig 3. Overview of mtDNAmutational signatures. Substitution patterns (mutational signatures) are shown
for each cancer type, which each substitution class labeled by the pyrimidine of the Watson-Crick pair [31] but
with sense and antisense patterns shown separately to reveal strand biases. Bars indicate enrichment
relative to the expected frequency (observed/expected ratio) for all possible substitutions, taking into account
the nucleotide composition of mtDNA and assuming equal probability for all three substitutions. L, light
strand; H, heavy strand.
doi:10.1371/journal.pgen.1005333.g003
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differentially transcribed or processed. In the nuclear genome, allelic imbalances arise fre-
quently due to, for example, genomic imprinting or RNA surveillance (nonsense-mediated
decay, NMD) [34], but no large-scale studies have been done in mitochondria.
Allelic ratios in general were highly consistent between DNA and polyA+ RNA (r = 0.91;
Fig 4A). However, a subset of the mutant alleles showed clearly elevated frequencies in the
polyA+ RNA pool (Fig 4A). Interestingly, of 15 mutations with marked elevation in RNA (fre-
quency difference> 0.3; red dots in Fig 4A), 12 (80%) were found to localize to mt-tRNA
regions, to be compared with 33/601 (5.5%) in the remaining set (P = 2.0e-12, Fisher’s exact
test). Mature mt-tRNAs are not polyadenylated, in contrast to other mitochondrial RNA prod-
ucts and precursors, and thus should not appear in these sequencing libraries [9]. The elevated
frequency in mRNA data for some mutant tRNA alleles is therefore most likely explained by a
failure to process and clear the mutant molecules from the polyA+ precursor pool, causing
accumulation relative to their wild type counterparts. We selected this set of mt-tRNA muta-
tions with elevated frequency in RNA for further study, as they might provide insight into
properties and requirements for mt-tRNA maturation.
It has previously been observed that some disease-associated mt-tRNA mutations that affect
the secondary and tertiary structure can lead to the accumulation of processing intermediates
[20,21]. We therefore compared the set of mt-tRNA mutations with elevated frequency in
polyA+ RNA (Fig 4A, red dots) to remaining mt-tRNA mutations, with respect to the pre-
dicted structural impact (Methods). This revealed a significant difference in the predicted abil-
ity to disrupt the tRNA secondary structure, where most mutations with a strong predicted
impact were in the category with elevated RNA allele frequency (Fig 4B, P = 0.038, Wilcoxon
rank sum test; S1 Table). Similar results were obtained by instead applying a cutoff to the struc-
tural score followed by enrichment testing (S2 Table). Fig 4C shows an example of a T37C
mutation in the tRNAIle, where the substitution is predicted to alter the predicted cloverleaf
fold to a non-canonical structure (see S3 Fig for more details). As an alternative approach, we
used established mt-tRNA structures [37] to determine whether mutations localized to loop or
stem regions, arguing that the latter would be more likely to affect structure. All of the 12 muta-
tions with marked accumulation in RNA localized to stems, compared to 23/33 for remaining
mt-tRNA mutations (P = 0.042, Fisher’s exact test). These results support that structure is a
major determinant for proper mt-tRNA recognition and processing.
Next, we carefully examined expression levels (normalized polyA+ RNA-seq read coverage)
in the areas surrounding the 12 tRNA mutations with marked allelic imbalance, comparing
mutated to non-mutated tumors. In most cases, levels were elevated throughout the respective
tRNAs, and often also in neighboring genes (discussed below), further supporting accumula-
tion of polycistronic polyA+ precursors containing unprocessed tRNAs (Fig 4D). Increases
compared to non-mutated control tumors were often dramatic (up to 100-fold), and the mild-
est variations were seen for the three mutations with the least DNA/RNA allelic imbalance
(tRNAAsp, tRNATrp, and tRNAMet). Expression patterns for other tRNA mutations were in gen-
eral more similar to controls (S4 Fig), and when processing was still clearly affected this was
typically explained by a difference in DNA/RNA frequency close to the threshold used here
(0.3) or, alternatively, a high mutant allele frequency in DNA, making it hard to detect further
accumulation in RNA. Similar patterns of precursor accumulation have been observed when
knocking down components of the mt-tRNA maturation pathway [18].
Finally we investigated how impaired processing of specific mt-tRNAs affected the matura-
tion of neighboring genes, since cleavage at mt-tRNA boundaries is key to converting the mito-
chondrial large polycistronic RNAs into smaller gene products (Fig 4D). Eight mutations
occurred in the ND1-tRNAIle-antisense tRNAGln-tRNAMet-ND2 cluster of tRNAs. Four
observed mutations in tRNAIle all led to accumulation of intermediates where both tRNAIle
DNA/RNAMapping of Mitochondrial Mutations in Cancer
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Fig 4. Comparison of allelic ratios in DNA and RNA reveals allelic imbalances consistent with impaired tRNA processing. (a) Scatter plot of allele
frequencies (heteroplasmy levels) in DNA vs. RNA for all 616 mutations (r = 0.91). 15 mutations with marked accumulation in polyA+ RNA relative to DNA
(frequency difference > 0.3) are indicated in red. 12 of these 15 mutations were in tRNAs regions (numbered 1–12 in superscript), indicative of impaired
processing of the polyA+ precursor RNA to a mature polyA- tRNA. (b) tRNAmutations accumulated in polyA+ RNA (red in panel a) showed elevated
predicted RNA structural impact, determined using the RNAsnp tool [35,36], compared to other tRNAmutations (P = 0.038, Wilcoxon rank sum test). The
comparison was based on 9 and 9 inhibiting/non-inhibiting mutations (cases where the wild-type sequence failed to fold into a tRNA-like structure were
excluded). The dotted line indicates an RNAsnp P-value (structural impact score) of 0.2 (c) Example RNAsnp result for a U to C mutation in position 37 of the
mitochondrial isoleucine tRNA. The dot-plot shows the ensemble base-pair probabilities of the wild type (upper triangle) and mutant (lower triangle)
sequences, with the altered local region indicated in gray. Wild type and mutant minimum free energy structures are shown (altered local region in color). (d)
Normalized RNA read coverage, showing relative (per-tumor normalized) polyA+ expression levels across the mitochondrial genome in mutated tRNA
regions for the 12 tRNAmutations indicated in panel a (each identifiable by a superscript number). Mutated cases (yellow) are compared to controls (green,
median of all non-mutated cases). Gene strand orientation is indicated by arrows (right-facing: L-strand). Mutated positions are indicated by triangles.
Samples IDs are shown in gray. tRNA genes are referred to as “TX”, where X = the single letter amino acid code.
doi:10.1371/journal.pgen.1005333.g004
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and antisense tRNAGln remained at the 3´ end of ND1 while processing of the 3´-encoded
tRNAMet was unaffected. This supports that many mt-tRNA mutations may have a functional
impact on neighboring coding genes, since polyadenylation at the correct site can be crucial for
mRNA function [38]. Interestingly, mutations in the acceptor stem of tRNAMet in two cases
instead lead to the accumulation of intermediates with anti-sense tRNAGln and tRNAMet
remaining 5´ of ND2. Processing of the 5´-encoded tRNAIle was also moderately impaired in
these cases. This implies that tRNAIle can be processed from the mutant RNA species, but less
efficiently. Our observations are consistent with a model whereby 3´ to 5´ removal of the
tRNAs within a multi-tRNA cluster is more efficient than 50 to 30 or uncoordinated processing
order [39] (Fig 5).
Discussion
Sequencing data from TCGA here enabled us to identify and characterize somatic mutations in
mtDNA across a diverse landscape of human cancers. In our study, we have considered dual
evidence from both DNA and RNA in a comprehensive patient cohort, for the first time
enabling a systematic analysis of mitochondrial DNA/RNA allelic imbalances across a large
Fig 5. Proposedmodel of mt-tRNA processing in light of observed RNA species in human cancers.
The normal processing cascade is depicted (left-hand side). The data in Fig 4 suggests that proper folding of
the pre-tRNAs is important for RNAse P/Z processing. Structure-disrupting mutations in tRNAIle allow for
normal processing of the tRNAMet, but leave polyA+ processing-intermediate products with mutation-bearing
tRNAIle and the antisense-tRNAGln sequences on the 3’ end ofND1 (middle). This implies that the antisense
tRNAGln is not a substrate for tRNA processing endonucleases. Structure-disrupting mutations in the tRNAMet
gene lead to the accumulation of intermediates in which the antisense tRNAGln and mutation-bearing
tRNAMet sequences remain attached to the 5’ end of theND2 gene (right-hand side). Processing of the wild
type tRNAIle still occurs but at reduced efficacy, consistent with a model whereby processing of a multi-tRNA
cluster occurs preferably in the 3’ to 5’ direction.
doi:10.1371/journal.pgen.1005333.g005
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number of samples. We additionally provide confirmatory results regarding purifying selection
in coding regions as well as the basic mutational signature of somatic mtDNA changes in
tumors [8].
In agreement with [8], we believe that the dramatic mutational strand bias likely relates to
the fact that the mode of replication differs between the two mtDNA strands [32]. According
to the strand displacement model for mtDNA replication, H-strand replication requires the
TWINKLE DNA helicase to unwind the double-stranded mtDNA genome, whereas L-strand
synthesis is performed using the displaced, single-stranded parental H-strand as template. The
nature of the template in the two reactions (dsDNA vs. ssDNA) will most likely affect both rate
and processivity of mtDNA replication, which in turn can cause unequal fidelity of L-strand
and H-strand synthesis. Alternatively, the strand bias could be due to hydrolytic deamination
of C to U, which is more likely to occur on the single-stranded parental H-strand. Arguing
against this model is the absence of a gradient coinciding with the duration of single strand
exposure during mtDNA replication, i.e. higher levels of C>T mutations closer to the control
region and a gradual drop towards the origin of L-strand replication [40].
The dual DNA/RNA design of this study allowed us to investigate how somatic mtDNA
changes were reflected at the transcriptomic level. Allelic ratios overall were concordant
between DNA and RNA, despite the presence of many frame-shifting or stop-codon inducing
mutations in our compendium. Importantly, this argues against the presence of potent muta-
tion-dependent mRNA surveillance mechanisms akin to nonsense-mediated decay in mito-
chondria. Conversely, there was no evidence for mutation-induced increases in the levels of
individual mRNA transcripts. However, a small number of mutations, mostly in tRNA genes,
showed a curious excess of the mutated allele in polyA+ RNA-seq compared to DNA, indica-
tive of impaired processing from a polyA+ precursor into a polyA- mature tRNA. This phe-
nomenon helped to confirm hypotheses regarding processing of mt-tRNAs, including a role
for the tRNA fold in recognition by processing endonucleases, as these mutations were associ-
ated with impaired tRNA structure. Mutations in mt-tRNAs underlie a range of conditions,
including neural, gastrointestinal and muscular disorders [19]. While the underlying mecha-
nisms are variable and poorly understood, is has been noted that pathological variants often
localize to stem regions of the cloverleaf-like mt-tRNA structure, suggestive of a structural
impact [19]. Our data suggests that mutations affecting tRNA folding may impair maturation
of not only the affected tRNA, but also neighboring gene transcripts. This could be an impor-
tant part in the pathology of many disease-associated mt-tRNAs variants and may explain why
mutations in the same tRNA may present radically different disease phenotypes.
Of interest is the behavior of the antisense tRNAGln sequence, clustered between the tRNAIle
and tRNAMet genes. Mutations in either of the flanking tRNAs lead to accumulation of polyA+-
intermediates for this element, suggesting that this antisense tRNA is not able to adopt a confir-
mation identified by the processing enzymes, and instead behaves simply as an RNA spacer.
More work is needed to determine whether this can be generalized to other analogous mtDNA
regions. In the same cluster, we found that processing of tRNAMet appeared unaffected by
mutations in tRNAIle. Interestingly, the converse was not true, as processing of tRNAIle was par-
tially affected by mutations in tRNAMet, most evidently at the 3´ side of tRNAIle (Fig 4D). It has
previously been reported in the fruitfly Drosophila melanogaster, that mitochondrial tRNA
processing appears to occur in a 3´ to 5´ manner [39,41]. Our data supports model whereby
processing of preferably occurs in the 3´ to 5´ direction, but where 5´ encoded tRNAs may still
be identified and liberated at lower efficacy.
The nuclear genome has in recent years been extensively surveyed with respect to somatic
mutations in tumors. A massive body of available sequencing data pertaining to the mitochon-
drial genome and transcriptome, generated as a byproduct of these surveys, remains curiously
DNA/RNAMapping of Mitochondrial Mutations in Cancer
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understudied. Controlled manipulation of mtDNA is difficult, as standard genetic tools are not
applicable to mitochondria. In the present work, we have demonstrated how a large compen-
dium of genetic perturbations, derived from human tumor sequencing data, can provide basic
insight into mitochondrial function.
Methods
Mutation calling in DNA and RNA
WGS data in bam format (Hg19 assembly) from 527 tumor/normal pairs sequencing by the
TCGA were obtained from the cgHub repository (S1 Dataset). This set included non-embar-
goed tumors with a minimum file size of 75 GB, where matching RNA-seq data was available.
Colon and rectal carcinoma samples (COAD/READ) were merged into one cancer type
(CRC). Somatic mutations were called with VarScan27 essentially as described previously [42]:
we used samtools (commandmpileup with default settings and additional options-q1 and–B)
and VarScan in somatic mode with the additional option–strand-filter 1). We required a mini-
mum variant frequency of 15%, P-value below 0.001 was required, and a variant frequency
below 0.5% in the normal. WGS mutation calling was performed at the UPPMAX HPC Center
(Uppsala, Sweden).
The default alignment protocol employed by the TCGA for RNA-seq is not optimal for
mutation calling, and indels in particular will not be properly called. RNA-seq data was there-
fore realigned to the chrM_rRCS reference using bwa [43] (options–q 5 and-l 32). This was fol-
lowed by GATK’s IndelRealigner [44] (default parameters) to correct misaligned indels. Lastly,
somatic mutations were detected as described above but using the parameters–E and–q25
parameters for mpileup and—min-var-freq 0.02 for VarScan.
Expression coverage plots
Expression level plots across the mitochondrial genome (polyA+ RNA-seq read coverage data)
were determined using the bedtools[45] genomecov command, based on realigned data as
described above. The coverage data was normalized by dividing by the total number of reads
aligned to chrM in each sample.
Assessing structural impact of tRNA mutations
For mutations in mitochondrial tRNAs, we used RNAsnp (v1.1) [35,36] to determine whether
there was a likely impact on the structure. Briefly, this tool will fold the wild-type and the
mutated RNA, and determine a score (and P-value) that reflects the extent to which the sec-
ondary structures differ. For the P-value calculation, RNAsnp uses one of several pre-com-
puted background distribution of scores available for different sequence lengths. For our
analysis, we chose the lowest sequence length (200nts) available using the parameter '-w 100'
along with 'Mode 1' (Euclidean distance measure). However, to avoid any biases in the P-value
calculation due to the differences in the sequence length match, we also generated new back-
ground scores by using random sequences of length similar to the tRNA sequences by follow-
ing the procedure described in [35], except that the random sequences were generated by di-
nucleotide preserved shuffling of tRNA sequences. The P-values computed using this new
background scores correlate well with the default P-values from pre-computed background
scores (S5 Fig). tRNAs where the native structure did not fold properly (based on comparison
of predicted base pairs of wild-type ensemble structure with the reference secondary structure
fromMamit-tRNA [46] and tRNAdb databases [37]) were excluded from analysis, which
resulted in 18 cases of tRNA mutations that could be further analyzed (see S1 Table and S3
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Fig). RNAsnp P-values (using the new background distribution) for mutations that showed
allelic imbalances, indicative of processing defects (allelic ratio difference>0.3; red in Fig 4A),
were finally compared to those of mutations that showed expected allelic ratios.
Supporting Information
S1 Fig. Histogram of read coverage in WGS for all identified somatic mutations. The aver-
age read coverage for the 616 somatic mutations was 5342 in the tumors and 3751 in the nor-
mals (minimum 279 and 118, respectively).
(PDF)
S2 Fig. Position-specific mutational signatures throughout the mitochondrial genome.
Blab. The circular mitochondrial genome was divided into 50 segments of 331 nt. The muta-
tional signature for each segment was determined similarly to main Fig 1, but with overrepre-
sented mutational events indicated using a color code instead of bar graphs.
(PDF)
S3 Fig. Detailed graphical output of RNAsnp predictions. (a) Base-pair probabilities: The
upper and lower triangle of the matrix represents the ensemble base pair probabilities of wild-
type and mutant sequences, respectively. In case of wild-type, the base pairs that match with
the reference tRNA secondary structure [37,46] are highlighted in light green color. The local
region detected with maximum base pair changes is highlighted in gray background. (b) and
(c) Minimum free energy structures of the wild-type and mutant sequences, respectively. The
region highlighted in different colour corresponds to the local region as detected in the above
base pairing probability matrix (a).
(PDF)
S4 Fig. Additional RNA read coverage plots. The plots show relative (per-tumor normalized)
polyA+ expression levels across the mitochondrial genome in mutated regions for additional
mutations not included in Fig 4A and 4D. All additional mutations in with allele frequency
difference> 0.3 or< -0.3 are shown, as well as all tRNA mutations in the -0.3. . .0.3 range. All
Mutated cases (red) are compared to controls (blue, median of all non-mutated cases). Mutated
positions are indicated by triangles. VAFDNA, variant allele frequency in DNA; VAFRNA, vari-
ant allele frequency in RNA.
(PDF)
S5 Fig. Comparison of RNAsnp P-values computed using default and tRNA-adapted back-
ground scores.
(PDF)
S1 Appendix. Comparison of observed synonymous:nonsynonymous ratios to an expected
null model.
(PDF)
S1 Dataset. Information regarding sequencing libraries included in the study.
(XLSX)
S2 Dataset. Detailed catalogue of somatic mutations identified across the 527 tumors con-
sidered in the study, including allele frequencies in DNA and RNA. The table includes 644
mutations identified using WGS, of which 616 where confirmed in RNA-seq.
(XLSX)
S1 Table. Somatic mutations in mt-tRNAs. DNA and RNA allele frequencies are indicated,
as well as predicted structural impact determined using RNAsnp. The column “Native
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structure predicted” represents whether the wild-type secondary structure predicted by
RNAsnp match the reference tRNA secondary structure (clover-leaf structure) [37,46] (see S3
Fig for more details).
(PDF)
S2 Table. Enrichment analysis of structure-disruptive mutations in the processing defect
group compared to no processing defect group, under different RNAsnp P-value cut-offs.
(PDF)
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